Unveiling the New COPD Era: Biologics, Guidelines, and Real-World Challenges
The management of chronic obstructive pulmonary disease (COPD) has witnessed a transformative shift over the past decade, marking a new era in patient care. Once dominated by inhaled bronchodilators and corticosteroids, treatment strategies are now expanding to encompass a more comprehensive, biologically-driven approach. This evolution is driven by a growing understanding of COPD as a diverse condition, characterized by various phenotypes and inflammatory patterns, which necessitates a more tailored and precise treatment strategy.
A significant milestone in this journey was the 2024 approval of dupilumab for eosinophilic COPD, offering a novel therapeutic option for patients who have not responded adequately to conventional inhaled treatments. This breakthrough was followed by the approval of mepolizumab in 2025, and ongoing research into new therapies continues to advance. As the excitement around these biologics grows, so do the practical considerations surrounding patient selection, real-world effectiveness, biomarker fluctuations, and navigating payer constraints to ensure patient access.
In the context of these advancements, a recent clinical forum hosted by HCPLive brought together experts, including MeiLan K. Han, MD, MS, to discuss the front-line experiences of pulmonologists and severe-airways specialists in incorporating biologics into COPD management. The discussion delved into the complexities of diagnosing airway diseases, interpreting eosinophil levels in clinical practice, distinguishing between asthma-COPD overlap and pure COPD, and reorienting management towards treatable traits rather than rigid step-up protocols.
The forum highlighted ongoing challenges in COPD management, such as misdiagnosis, delayed referrals, inhaler misuse, and inconsistent patient adherence, which have persisted despite the introduction of new therapies. These issues significantly impact patient response to treatments, emphasizing the need for a comprehensive approach to diagnosis and management.
One panelist shared an interesting perspective, explaining the use of dupilumab in patients without documented high eosinophils, considering the potential impact of corticosteroid use. This highlights the complexity of patient selection and the need for a nuanced approach to treatment.
A recurring theme was the importance of deeper phenotyping at the point of care, involving careful interpretation of eosinophils, exacerbation patterns, imaging results, and symptom profiles to differentiate between true COPD, asthma-COPD overlap, and mixed inflammatory states. Participants stressed that eosinophil levels should guide treatment decisions but not dictate them, acknowledging the variability of these biomarkers over time and the significance of the broader clinical context.
When discussing roflumilast, a panelist noted that the most significant benefits are observed in patients with frequent exacerbations. However, they also mentioned the challenge of finding patients who can tolerate roflumilast, indicating the need for personalized treatment approaches.
The forum also explored the practical deployment of biologics in real-world settings, with clinicians sharing their criteria for initiating therapy in patients with persistent symptoms or frequent exacerbations despite optimized triple therapy. They discussed operational barriers associated with biologics, such as documentation, insurance approvals, infusion logistics, and the crucial role of collaboration between pulmonologists, primary care physicians, pharmacists, and payers.
One participant emphasized the importance of educating primary care physicians on COPD management, addressing their lack of training and the tendency to delay referrals and overprescribe parenteral steroids. This highlights the need for a comprehensive education campaign to equip healthcare professionals with the knowledge to recognize and promptly refer patients to specialists.
In conclusion, the key takeaway from the discussion was the shift towards a more individualized, treatable-traits-driven model of COPD care. This approach emphasizes the use of biologics when appropriate while maintaining a strong foundation in foundational elements such as inhaler technique, pulmonary rehabilitation, risk-factor modification, and ongoing patient engagement.
This comprehensive and individualized approach promises to revolutionize COPD management, offering patients with diverse phenotypes and inflammatory patterns the best possible care.
